Michael Gelband’s Tango Therapeutics TNGX Stock Holding History

Michael Gelband’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.06M	Buy	+98,015	New	+$2.42M	0.02%	656
2026 Q1	–	Sell	-32,897	Closed	-$291K	–	2098
2025 Q4	$291K	Sell	32,897 -48,341	-60%	-$417K	﹤0.01%	1318
2025 Q3	$682K	Buy	+81,238	New	+$550K	0.01%	1088
2025 Q1	–	Sell	-121,993	Closed	-$377K	–	1988
2024 Q4	$377K	Buy	+121,993	New	+$566K	﹤0.01%	1222
2022 Q2	–	Sell	-192,325	Closed	-$1.46M	–	2453
2022 Q1	$1.46M	Buy	192,325 +126,824	+194%	+$1.1M	0.02%	938
2021 Q4	$717K	Buy	+65,501	New	+$788K	0.01%	1239
2021 Q1	–	Sell	-10,000	Closed	-$114K	–	2608
2020 Q4	$114K	Buy	+10,000	New	+$105K	﹤0.01%	1818

Other funds holding TNGX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Michael Gelband's TNGX Position: Q2 2026 in Review

Michael Gelband opened a new position in Tango Therapeutics (TNGX) in Q2 2026: 98,015 shares worth $3.06M. The stake represents 0.02% of the portfolio and ranks #656 among its holdings. This is a return to the name: Michael Gelband previously reported a position in TNGX as recently as Q4 2025.

Michael Gelband first reported a position in TNGX in Q4 2020 and has held it in 7 quarters since. 246 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

Michael Gelband held 98,015 shares of Tango Therapeutics worth $3.06M as of Q2 2026.
Tango Therapeutics was a new Michael Gelband position in Q2 2026.
Tango Therapeutics made up 0.02% of Michael Gelband's portfolio in Q2 2026, its #656 holding.
Michael Gelband first reported a position in Tango Therapeutics in Q4 2020 and has held it in 7 quarters since.
246 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.